Brokerages Set AngioDynamics, Inc. (ANGO) PT at $20.00

AngioDynamics, Inc. (NASDAQ:ANGO) has been assigned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $20.00.

A number of research analysts have recently weighed in on ANGO shares. BidaskClub lowered AngioDynamics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 1st. Canaccord Genuity reissued a “hold” rating and issued a $20.00 price objective on shares of AngioDynamics in a report on Thursday, July 12th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a report on Tuesday, September 11th. Finally, Raymond James lowered AngioDynamics from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 11th.

Shares of ANGO opened at $21.71 on Monday. The company has a current ratio of 2.64, a quick ratio of 1.55 and a debt-to-equity ratio of 0.16. The stock has a market cap of $789.95 million, a PE ratio of 29.34 and a beta of 0.75. AngioDynamics has a twelve month low of $15.16 and a twelve month high of $24.49.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, September 27th. The medical instruments supplier reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The firm had revenue of $85.34 million during the quarter, compared to analyst estimates of $84.05 million. AngioDynamics had a net margin of 4.62% and a return on equity of 5.44%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the company posted $0.13 earnings per share. As a group, sell-side analysts predict that AngioDynamics will post 0.85 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. grew its holdings in AngioDynamics by 1.1% during the third quarter. American Century Companies Inc. now owns 241,276 shares of the medical instruments supplier’s stock worth $5,245,000 after acquiring an additional 2,721 shares during the period. Bank of America Corp DE grew its holdings in AngioDynamics by 12.9% during the second quarter. Bank of America Corp DE now owns 29,191 shares of the medical instruments supplier’s stock worth $649,000 after acquiring an additional 3,344 shares during the period. Legal & General Group Plc grew its holdings in AngioDynamics by 5.4% during the second quarter. Legal & General Group Plc now owns 72,459 shares of the medical instruments supplier’s stock worth $1,614,000 after acquiring an additional 3,707 shares during the period. Royal Bank of Canada grew its holdings in AngioDynamics by 3.3% during the first quarter. Royal Bank of Canada now owns 126,439 shares of the medical instruments supplier’s stock worth $2,181,000 after acquiring an additional 3,981 shares during the period. Finally, Port Capital LLC grew its holdings in AngioDynamics by 32.5% during the second quarter. Port Capital LLC now owns 16,325 shares of the medical instruments supplier’s stock worth $363,000 after acquiring an additional 4,000 shares during the period. 97.54% of the stock is currently owned by hedge funds and other institutional investors.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: Buyback

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply